Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05997030 · ClinicalTrials.gov registry record · NA

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

A NA study of Alzheimer Disease, sponsored by Ali Rezai.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT05997030 is a NA study of Alzheimer Disease that is actively recruiting participants, run by Ali Rezai. The registered enrollment target is 15 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05997030, a NA study of Alzheimer Disease, is actively recruiting participants, sponsored by Ali Rezai.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

Conditions Studied

Interventions

  • DEVICE low intensity focused ultrasound (LIFU)

Study Locations (1)

West Virginia

  • Rockefeller Neuroscience Institute at West Virginia University - Morgantown

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-10-12
Est. Completion 2026-09-30
Phase NA

Sponsor

Ali Rezai

4 total trials

What the Registry Record Tells You About NCT05997030

The ClinicalTrials.gov registry entry for NCT05997030 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Ali Rezai, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which low intensity focused ultrasound (LIFU) is the first listed.

NCT05997030 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.

Frequently Asked Questions

What is clinical trial NCT05997030 about?

NCT05997030 is a clinical study titled "Low-Intensity Focused Ultrasound (LIFU) Neuromodulation". This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

What is the current status of trial NCT05997030?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-10-12. Estimated completion is 2026-09-30.

What conditions does trial NCT05997030 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT05997030?

The interventions under investigation include: low intensity focused ultrasound (LIFU) (DEVICE).

Who is sponsoring clinical trial NCT05997030?

This trial is sponsored by Ali Rezai, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05997030 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.